LEAA Health membership-based concierge
patients will now have access to EsoGuard esophageal precancer
testing as part of their enhanced personalized care service on a
cash-pay basis
NEW
YORK, Feb. 20, 2025 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or
the "Company"), a commercial-stage, cancer prevention medical
diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM),
today announced that it has entered into its first concierge
medicine contract with LEAA Health. The contract provides LEEA
Health's membership-based patients access to groundbreaking
esophageal precancer testing using Lucid's EsoGuard®
Esophageal DNA Test. This expands LEAA Health's enhanced
personalized care services, which it offers to its patients on a
cash-pay basis. Lucid aims to drive contractually-guaranteed
revenue by capitalizing on the growing demand for
prevention-focused healthcare services in the expanding concierge
medicine market.
"We are thrilled to enter into our first concierge medicine
contract with LEAA Health to expand access to EsoGuard precancer
testing," said Shaun O'Neil, Lucid's
President and Chief Operating Officer. "We have committed to
growing contractually-guaranteed EsoGuard revenue in parallel with
our intensive efforts to secure Medicare and commercial coverage.
Our recently launched cash-pay program targeting concierge medicine
is an important component of this strategic initiative. Concierge
medicine patients actively seek innovative preventive care
solutions such as EsoGuard and we are pleased to offer our solution
as part of LEAA Health's enhanced personalized care offerings."
"This partnership with Lucid aligns perfectly with LEAA Health's
mission to provide top-tier, personalized healthcare solutions to
our patients," said Isaak N.
Yakubov, Founder and CEO of LEAA Health. "EsoGuard
represents a groundbreaking approach to esophageal precancer
detection, allowing us to identify potential issues at an early
stage when intervention can be most effective. By offering EsoGuard
as a screening tool to all eligible patients, we
are expanding access to this innovative test
and enhancing our ability to deliver proactive, personalized
care that could potentially save lives."
The 2024 Annual Report from Concierge Medicine Today indicates
that the concierge medicine market in the
United States is projected to reach $10.9 billion by 2032, reflecting the increasing
demand for personalized, prevention-focused healthcare
services.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company,
and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on
the millions of patients with gastroesophageal reflux disease
(GERD), also known as chronic heartburn, who are at risk of
developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck® Esophageal Cell Collection Device, represent
the first and only commercially available tools designed with the
goal of preventing cancer and cancer deaths through widespread,
early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
Forward-Looking Statements
This press release includes
forward-looking statements that involve risk and uncertainties.
Forward-looking statements are any statements that are not
historical facts. Such forward-looking statements, which are based
upon the current beliefs and expectations of Lucid's management,
are subject to risks and uncertainties, which could cause actual
results to differ from the forward-looking statements. Risks and
uncertainties that may cause such differences include, among other
things, volatility in the price of Lucid's common stock; general
economic and market conditions; the uncertainties inherent in
research and development, including the cost and time required to
advance Lucid's products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and
results from Lucid's clinical and preclinical studies; whether and
when Lucid's products are cleared by regulatory authorities; market
acceptance of Lucid's products once cleared and commercialized;
Lucid's ability to raise additional funding as needed; and other
competitive developments. In addition, Lucid continues to monitor
the COVID-19 pandemic and the pandemic's impact on Lucid's
businesses. These factors are difficult or impossible to predict
accurately and many of them are beyond Lucid's control. In
addition, new risks and uncertainties may arise from time to time
and are difficult to predict. For a further list and description of
these and other important risks and uncertainties that may affect
Lucid's future operations, see Part I, Item 1A, "Risk Factors," in
Lucid's most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, as the same may be updated in
Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form
10-Q filed by Lucid Diagnostics after its most recent Annual
Report. Lucid disclaims any intention or obligation to publicly
update or revise any forward-looking statement to reflect any
change in its expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-executes-first-concierge-medicine-contract-with-leaa-health-302381394.html
SOURCE Lucid Diagnostics